Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shot up 9.9% during mid-day trading on Wednesday . The company traded as high as $4.50 and last traded at $4.44, 4,745,848 shares changed hands during trading. A decline of 44% from the average session volume of 8,469,285 shares. The stock had previously closed at $4.04.
ADAP has been the subject of a number of recent analyst reports. Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Friday. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. Finally, ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $5.86.
The stock’s 50-day moving average is $1.56 and its 200-day moving average is $1.75. The firm has a market cap of $470.06 million, a P/E ratio of -4.71 and a beta of 1.83. The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 0.15.
Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $7.00 million. As a group, analysts expect that Adaptimmune Therapeutics PLC – will post -1.37 EPS for the current fiscal year.
In other news, Director James Noble sold 300,000 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $4.67, for a total transaction of $1,401,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 317,323 shares of company stock worth $1,447,506. Insiders own 22.36% of the company’s stock.
Large investors have recently made changes to their positions in the company. Man Group plc increased its position in shares of Adaptimmune Therapeutics by 37.4% during the second quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock valued at $7,394,000 after purchasing an additional 500,595 shares during the period. Bamco Inc. NY boosted its stake in Adaptimmune Therapeutics by 6.1% during the second quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock worth $694,000 after buying an additional 10,000 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Adaptimmune Therapeutics by 21,372.0% during the third quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock worth $32,000 after buying an additional 21,372 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Adaptimmune Therapeutics by 5.2% in the 3rd quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock valued at $1,380,000 after buying an additional 45,249 shares during the period. 65.06% of the stock is currently owned by institutional investors.
Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.